Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin-(1-7) Cardiovascular Effects in Aging
NCT05301192Phase 1Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of angiotensin-(1-7) in hypertension (HTN) and cardiovascular disease (CVD) (2 arms), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Change in Muscle Sympathetic Nerve Burst Rate at 110 minutes. Started Dec 2022; status: terminated.
02
Drugs
angiotensin-(1-7)
03
Conditions
hypertension (HTN)cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT05301192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05301192.